###begin article-title 0
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
###xml 114 117 <span type="species:ncbi:9606">man</span>
Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man?
###end article-title 0
###begin p 1
###xml 368 369 368 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 374 376 374 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 551 561 551 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bona fide </italic>
###xml 495 500 <span type="species:ncbi:9606">human</span>
###xml 516 521 <span type="species:ncbi:10090">mouse</span>
Identification of breast cancer stem cells as the cells within breast tumors that have the ability to give rise to cells that make up the bulk of the tumor mass has shifted the focus of cancer research. However, there is still much debate concerning the unique nature of the markers that distinguish cancer stem cells in the breast. As such, understanding whether CD44+/CD24- breast cancer cells are merely more successful in overcoming an engraftment incompatibility that exists when injecting human cells into the mouse adipose tissue or are indeed bona fide cancer stem cells is of great importance.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 99 109 99 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bona fide </italic>
###xml 257 258 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 776 777 776 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1027 1028 1027 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1033 1034 1033 1034 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1038 1040 1038 1040 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 696 701 <span type="species:ncbi:9606">human</span>
###xml 794 799 <span type="species:ncbi:9606">human</span>
###xml 963 967 <span type="species:ncbi:10090">mice</span>
###xml 1040 1045 <span type="species:ncbi:9606">human</span>
Although the theory of cancer stem cells dates back more than 50 years, the existence of the first bona fide tumorigenic cell compartment was not demonstrated until 1994, when the acute myelogenous leukemia stem cell (LSC) was identified and characterized [1]. Since then, despite accumulating evidence that LSCs are responsible for maintenance and transfer of blood cancers, researchers doubted the existence of an analogous cell type in solid tumors. In fact, it was believed that every cell from a tumor had an equal likelihood of seeding a secondary cancer as long as it was in the correct microenvironment. However, in 2003 an influential report describing the prospective identification of human breast cancer stem cells changed the landscape of breast cancer research [2]. Using various human tumor samples (eight pleural effusions and one primary tumor), which were xenografted into the mammary glands of nonobese diabetic/severe combined immunodeficient mice, the investigators reported that a small population of CD44+/CD24-/Lin- human breast cancer cells were enriched for tumorigenic potential.
###end p 3
###begin p 4
Most researches now consider that, like leukemia, solid tumors such as prostate, breast, colon, brain, and pancreatic cancers contain a small fraction of self-renewing tumorigenic cells that give rise to and maintain the bulk of the tumor mass. The use of Hoescht dye efflux, suspension sphere assays, and serial transplantation are all proposed methods for identifying and separating cancer stem cells from solid tumors. However, arguably the most effective method of identifying these cells, which may be morphologically indistinct from the bulk of the cancer, is through differential cell surface protein expression.
###end p 4
###begin title 5
The choice and relevance of solid tumor markers
###end title 5
###begin p 6
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 176 178 176 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 529 530 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 531 532 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 394 399 <span type="species:ncbi:9606">human</span>
###xml 481 487 <span type="species:ncbi:10090">murine</span>
###xml 595 600 <span type="species:ncbi:9606">human</span>
###xml 678 683 <span type="species:ncbi:10090">mouse</span>
###xml 695 700 <span type="species:ncbi:9606">human</span>
###xml 787 792 <span type="species:ncbi:10090">mouse</span>
###xml 814 820 <span type="species:ncbi:9606">humans</span>
The relevance of current cancer stem cell markers for solid tumors remains controversial and perplexing. In leukemia, the rationale for using the cell surface makers CD34+/CD38- to identify LSCs was based on the known and shared markers for hematopoietic stem cells. However, in the case of breast cancer, the rationale for selection of prospective markers is less clear, primarily because the human breast stem cell has not yet been extensively characterized. Although a putative murine mammary stem cell was recently reported [3,4], the markers used in these studies have yet to be applied to human breast cancer stem cells. More importantly, even if researchers do apply the mouse markers to human cells, lessons learned from the hematopoietic field would suggest that the markers in mouse may not translate to humans (for instance, CD38 and Sca1).
###end p 6
###begin p 7
###xml 229 231 229 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 358 360 358 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 572 574 572 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 575 576 575 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 577 578 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 579 580 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 701 702 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 748 749 748 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 760 762 760 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 394 399 <span type="species:ncbi:9606">human</span>
###xml 457 461 <span type="species:ncbi:10090">mice</span>
For solid tumors, the repertoire of cell surface markers currently used to identify human cancer stem cells includes CD44, CD133, epithelial surface antigen (ESA), and CD24, either singly or in combination. Specifically, the CD44+ phenotype is correlated positively with colon, breast, prostate, and pancreatic cancer initiator cells [2,5-7]. Likewise, CD133+ cells have been shown to initiate human glioblastoma, colon, prostate, and pancreatic cancers in mice [5-8]. The phenotype of pancreatic and breast cancer initiator cells and normal breast progenitor cells is ESA+ [2,7,9]. Finally, CD24 has a more ambiguous past because it is positively correlated with tumorigenicity in pancreatic cancer [7] but negatively correlated in breast cancer [2], yet CD24+ cells are associated with invasive breast cancer [10].
###end p 7
###begin p 8
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 202 205 <span type="species:ncbi:10116">rat</span>
###xml 613 618 <span type="species:ncbi:9606">human</span>
The functional significance of these proteins is an area of investigation that remains poorly understood. It has been suggested that CD44 is an important molecule for metastasis because a nonmetastatic rat glioma cell line acquired metastatic properties when a splice variant of CD44 was ectopically over-expressed [11]. In addition, CD44 variant isoforms are differentially expressed during pregnancy and involution, indicating a role in normal breast epithelial homeostasis [12]. ESA is another molecule that deserves further investigation because it was shown to be essential for migration and invasion of the human breast cancer cell line MDA.MB.231 [13].
###end p 8
###begin p 9
###xml 338 346 338 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 349 357 349 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 763 764 763 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 765 766 765 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 767 768 767 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 393 398 <span type="species:ncbi:10090">mouse</span>
###xml 533 538 <span type="species:ncbi:9606">human</span>
###xml 661 666 <span type="species:ncbi:10090">mouse</span>
Regardless of the biologic activities of these markers, it is remarkable that the same cell surface markers enrich for tumor stem cells across many solid tumor types. Therefore, perhaps the markers that are currently used to identify 'stem cells' from solid tumors could actually be enriching for cells with certain functional properties in vivo or in vitro, namely to engraft successfully in mouse or to adhere and expand in culture. This theory is supported by the fact that nearly all studies on the prospective identification of human solid tumor stem cells have either xenografted the primary tumor into a nonobese diabetic/severe combined immunodeficient mouse, or briefly conditioned the tumor cells in culture before enriching for tumor initiating cells [2,5-7].
###end p 9
###begin title 10
What defines a cancer stem cell?
###end title 10
###begin p 11
###xml 227 235 227 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 305 311 <span type="species:ncbi:10090">murine</span>
###xml 336 341 <span type="species:ncbi:10090">mouse</span>
###xml 448 453 <span type="species:ncbi:9606">human</span>
###xml 502 507 <span type="species:ncbi:10090">mouse</span>
###xml 567 572 <span type="species:ncbi:10090">mouse</span>
The definition of a stem cell is the ability to self-renew and give rise to a daughter cell that is different from itself. The 'gold standard' in demonstrating stem cell activity is the ability to reconstitute a diverse tissue in vivo (normal or malignant). Although this is straightforward when studying murine stem cells, because the mouse serves as the natural host for engraftment studies, it is more complex when the only means for defining a human cancer stem cell is its ability to engraft in a mouse. Thus, if a cancer cell cannot successfully engraft into a mouse because of a species, hormonal, or micro-environment incompatibility, does this mean that the cell is not a cancer stem cell?
###end p 11
###begin p 12
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 115 121 <span type="species:ncbi:10090">murine</span>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
The importance of microenvironment was recently illustrated in an elegant study with leukemia [14]. In this study, murine LSCs deficient for CD44 introduced into the circulation of mice were unable to home to the bone marrow and thus could not form leukemia. However, the same CD44-deficient LSCs injected directly into the bone marrow were fully able to engraft and regenerate a heterogeneous tumor. Based on this work, it is clear that cancer stem cells that give rise to a heterogeneous tumor can exist, but if that same cell cannot engraft because of an incompatible microenvironment, should it no longer be defined as a cancer stem cell?
###end p 12
###begin p 13
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 56 58 56 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 752 753 752 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 758 760 758 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 103 108 <span type="species:ncbi:10090">mouse</span>
###xml 178 183 <span type="species:ncbi:9606">human</span>
###xml 197 203 <span type="species:ncbi:10090">murine</span>
###xml 270 275 <span type="species:ncbi:10090">mouse</span>
###xml 380 386 <span type="species:ncbi:10090">murine</span>
###xml 433 438 <span type="species:ncbi:9606">human</span>
###xml 491 496 <span type="species:ncbi:10090">mouse</span>
###xml 566 571 <span type="species:ncbi:9606">human</span>
###xml 902 907 <span type="species:ncbi:9606">human</span>
###xml 923 928 <span type="species:ncbi:10090">mouse</span>
For human breast cancers, is it the case that CD44+/CD24- cells are simply better at engrafting in the mouse mammary microenvironment, or are they really more tumorigenic in the human setting? The murine mammary gland is an excellent site for transplantation of primary mouse mammary epithelial cells (normal and neoplastic) because it is the natural stromal microenvironment for murine mammary cells. However, attempts to introduce human mammary epithelial cells (normal or malignant) into mouse mammary fat pads were only successful when the fibrous stroma of the human breast was recreated [15-17]. Because the stromal cells that are adjacent to cancer cells can facilitate their engraftment and tumor formation [16,18,19], it is plausible that CD44+/CD24- breast cancer cells are merely the cells that are the most successful in overcoming an engraftment incompatibility that exists when injecting human cells into the mouse adipose stroma.
###end p 13
###begin title 14
###xml 34 39 <span type="species:ncbi:9606">human</span>
The relevance of CD44 and CD24 in human breast cancer
###end title 14
###begin p 15
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 74 76 74 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 503 504 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 537 539 537 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 706 707 706 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 712 714 712 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 761 768 <span type="species:ncbi:9606">patient</span>
Several studies that have attempted to repeat and expand on the CD44+/CD24- breast cancer initiator cell profile have thus far been inconclusive. In 2004, a clinical study reported that there was no statistically significant CD44 or CD24 staining in primary breast cancer sections in relation to tumor grade, type, or size [20]. The authors postulated that one difference is that they use primary sections, in which a pathologist can identify tumor tissue, whereas in their study Al-Hajj and coworkers [2] used cell sorting to remove Lin- cells and subsequent flow cytometry. However, two more recent reports [21,22] have now confirmed, both in breast cancer derived cell lines and breast tumors, that CD44+/CD24- phenotypes are not necessarily associated with patient outcome or ability to metastasize.
###end p 15
###begin p 16
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 214 215 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 220 222 220 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 594 595 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 600 602 600 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 731 732 731 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 737 738 737 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1055 1057 1055 1057 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1167 1169 1167 1169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
In recent work, Shipitsin and coworkers [22] found that CD24 is expressed on more differentiated cells whereas CD44 is expressed on more progenitor-like cells. Specifically, they found that breast cells of the CD44+/CD24- phenotype express genes that are involved in cell motility and angiogenesis, are more mesenchymal, are motile, and are predominately estrogen receptor negative. In agreement with this study, we and others have also observed a strong association between breast cancer cells with a basal-like or mesenchymal-like phenotype (MDA.MB.231, SUM159, SUM1315) and the presence CD44+/CD24- cells (unpublished data, [21]). In contrast, cells with a more luminal, epithelial appearance (MCF7 and SUM225) were largely CD44-/CD24+, which is consistent with the luminal differentiated mucin-1-positive, estrogen receptor/progesterone receptor-positive, Gata3-positive cells reported by Shipitsin and coworkers. Taken together, these studies suggest another interesting interpretation of CD24 and CD44 as markers of breast cancer cells; perhaps CD44+ cells are predominately basal-like and therefore are present in poor prognosis basal-like tumors, whereas CD24+ cells are luminal-like and therefore present in more differentiated luminal-type cancers.
###end p 16
###begin title 17
Conclusion
###end title 17
###begin p 18
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 257 259 257 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
With the aim being to eradicate breast cancer, there is great interest and excitement in the possibility of identifying and treating the subpopulation of cancer stem cells that fuel tumor growth. However, there remains a need to determine whether CD44+/CD24- cells are true tumorigenic cells across all the various breast cancer subtypes, or whether these are unique to a more basal tumor type. Fortunately, the field is growing with the identification of new potential markers, such as protein C receptor [20], which may permit further enrichment and identification of therapeutic targets for treatment of breast cancer.
###end p 18
###begin title 19
Competing interests
###end title 19
###begin p 20
The authors declare that they have no competing interests.
###end p 20
###begin title 21
Acknowledgements
###end title 21
###begin p 22
We should like to thank the Susan Komen Foundation and the Breast Cancer Research Foundation. CK is a Raymond and Beverly Sackler Foundation Scholar.
###end p 22
###begin article-title 23
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
A cell initiating human acute myeloid leukemia after transplantation in SCID mice
###end article-title 23
###begin article-title 24
Prospective identification of tumorigenic breast cancer cells
###end article-title 24
###begin article-title 25
Generation of a functional mammary gland from a single stem cell
###end article-title 25
###begin article-title 26
Purification and unique properties of mammary epithelial stem cells
###end article-title 26
###begin article-title 27
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
A human colon caner cell capable of initiating tumour growth in immunodeficient mice
###end article-title 27
###begin article-title 28
Prospective identification of tumorigenic prostate cancer stem cells
###end article-title 28
###begin article-title 29
Identification of pancreatic cancer stem cells
###end article-title 29
###begin article-title 30
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification of human brain tumour initiating cells
###end article-title 30
###begin article-title 31
###xml 54 59 <span type="species:ncbi:9606">human</span>
Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties
###end article-title 31
###begin article-title 32
CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis
###end article-title 32
###begin article-title 33
###xml 67 70 <span type="species:ncbi:10116">rat</span>
A new variant of glucoprotein CD44 confers metastasis potential to rat carcinoma cells
###end article-title 33
###begin article-title 34
CD44 expression and regulation during mammary gland development and function
###end article-title 34
###begin article-title 35
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy
###end article-title 35
###begin article-title 36
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells
###end article-title 36
###begin article-title 37
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 65 70 <span type="species:ncbi:10090">mouse</span>
###xml 75 80 <span type="species:ncbi:9606">human</span>
A novel method for growing human breast epithelium in vivo using mouse and human mammary fibroblasts
###end article-title 37
###begin article-title 38
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
Reconstruction of functionally normal and malignant human breast tissues in mice
###end article-title 38
###begin article-title 39
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
Reconstruction of human mammary tissues in a mouse model
###end article-title 39
###begin article-title 40
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
###end article-title 40
###begin article-title 41
###xml 40 45 <span type="species:ncbi:9606">human</span>
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
###end article-title 41
###begin article-title 42
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 24 30 24 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/low </sup>
Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis
###end article-title 42
###begin article-title 43
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 10 12 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties, an early step necessary for metastasis
###end article-title 43
###begin article-title 44
Molecular definition of breast tumor heterogeneity
###end article-title 44

